4.5 Article

Fortasyn Connect Improves Neuropsychiatric Symptoms in Patients with Mild Cognitive Impairment and Dementia: Results from a Retrospective Real-World Study

Related references

Note: Only part of the references are listed.
Article Public, Environmental & Occupational Health

Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease 2019

Emma Nichols et al.

Summary: With projected trends in population ageing and growth, the number of people with dementia is expected to increase. Understanding the distribution and magnitude of anticipated growth is crucial for public health planning and resource prioritization, with a focus on potentially modifiable risk factors.

LANCET PUBLIC HEALTH (2022)

Article Clinical Neurology

Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography

Simon Holmgren et al.

Summary: The study aimed to explore the association between neuropsychiatric symptoms and electroencephalography (EEG) in patients with dementia, and to determine the clinical utility of using EEG for assessing pharmacological treatment of neuropsychiatric symptoms. The results showed a significant correlation between NPI agitation and delta EEG frequencies, but no consistent and significant relationships were observed between NPSD and EEG.

JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES (2022)

Article Neurosciences

Assessment of a Potential Synergistic Effect of Souvenaid® in Mild Alzheimer's Disease Patients on Treatment with Acetylcholinesterase Inhibitors: An Observational, Non-Interventional Study

Felix Vinuela et al.

Summary: In patients with mild Alzheimer's disease, the study found that co-administration of Souvenaid and AChE inhibitors or the use of Souvenaid alone resulted in lower monthly increases in CDR compared to using AChE inhibitors alone or receiving no treatment. The efficacy of Souvenaid + AChE inhibitors combination therapy tended to be higher than using Souvenaid alone.

JOURNAL OF ALZHEIMERS DISEASE (2021)

Article Clinical Neurology

Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality

Hong Xu et al.

Summary: The study showed that ChEIs are associated with a slower cognitive decline in Alzheimer's disease patients as well as a decreased risk of severe dementia or death. Galantamine was particularly effective in reducing mortality and the risk of severe dementia, while all ChEIs had a modest but persistent effect on cognitive benefits over time.

NEUROLOGY (2021)

Article Clinical Neurology

36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease

Hilkka Soininen et al.

Summary: The LipiDiDiet trial demonstrated that the specific multinutrient combination Fortasyn Connect has beneficial effects on cognition and disease progression in prodromal Alzheimer's disease, with greater benefits observed with long-term use.

ALZHEIMERS & DEMENTIA (2021)

Review Pharmacology & Pharmacy

An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease

Andrea Haake et al.

EXPERT OPINION ON DRUG SAFETY (2020)

Review Clinical Neurology

The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease

Marti Colom-Cadena et al.

ALZHEIMERS RESEARCH & THERAPY (2020)

Review Geriatrics & Gerontology

Depression, Anxiety, and Apathy in Mild Cognitive Impairment: Current Perspectives

Lina Ma

FRONTIERS IN AGING NEUROSCIENCE (2020)

Review Medicine, General & Internal

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

Gill Livingston et al.

LANCET (2020)

Article Clinical Neurology

Quality of life and disease burden in patients with MCI and dementia

Woori Moon

Alzheimers & Dementia (2020)

Review Clinical Neurology

Souvenaid in the management of mild cognitive impairment: an expert consensus opinion

Jeffrey Cummings et al.

ALZHEIMERS RESEARCH & THERAPY (2019)

Article Nutrition & Dietetics

Mediterranean Lifestyle in Relation to Cognitive Health: Results from the HELIAD Study

Costas A. Anastasiou et al.

NUTRIENTS (2018)

Review Clinical Neurology

Multi-Nutrient Dietary Intervention Approach to the Management of Alzheimer's Disease - A Mini-Review

Blanka Klimova et al.

CURRENT ALZHEIMER RESEARCH (2016)

Review Pharmacology & Pharmacy

Is synaptic loss a unique hallmark of Alzheimer's disease?

Stephen W. Scheff et al.

BIOCHEMICAL PHARMACOLOGY (2014)

Article Geriatrics & Gerontology

Quality of life in patients with mild cognitive impairment

Helena Barrios et al.

AGING & MENTAL HEALTH (2013)

Article Geriatrics & Gerontology

Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults

Stefan Van der Mussele et al.

INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2013)

Article Neurosciences

Efficacy of Souvenaid in Mild Alzheimer's Disease: Results from a Randomized, Controlled Trial

Philip Scheltens et al.

JOURNAL OF ALZHEIMERS DISEASE (2012)

Article Clinical Neurology

Behavioral and Psychological Symptoms of Dementia

J. Cerejeira et al.

Frontiers in Neurology (2012)

Article Geriatrics & Gerontology

Neuropsychiatric symptoms and Quality of Life in patients with very mild and mild Alzheimer's disease

Kristiina Karttunen et al.

INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2011)

Article Geriatrics & Gerontology

Neuropsychiatric Symptoms and the Risk of Institutionalization and Death: The Aging, Demographics, and Memory Study

Toru Okura et al.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2011)

Article Clinical Neurology

Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial

Philip Scheltens et al.

ALZHEIMERS & DEMENTIA (2010)

Review Neurosciences

Synapse Loss in Dementias

Ryan Clare et al.

JOURNAL OF NEUROSCIENCE RESEARCH (2010)